The gene for tumor necrosis factor, TNF, was expressed in 45 out of 63 biopsies of human epithelial ovarian cancer. In serous tumors, there was a positive correlation between level of TNF expression and tumor grade. TNF mRNA was found in epithelial tumor cells and infiltrating macrophages, whereas TNF protein localized primarily to a subpopulation of macrophages within and in close proximity to tumor areas. mRNA and protein for the p55 TNF receptor gene localized to the tumor epithelium and tumor, but not to stromal macrophages. The p75 TNF receptor was confined to infiltrating cells. Cells expressing TNF mRNA were also found in ovarian cancer ascites and TNF protein was detected in some ascitic fluids. In 2 out of 12 biopsies of normal ovary, TNF mRNA was detected in a minority of cells in the thecal layer ofthe corpus luteum. Serum levels of TNF and its soluble receptor did not correlate with extent of
Introduction
When the gene encoding human TNF was cloned in 1984 (1) , there was great interest in this factor as a new therapy for cancer. Both the historical background (2) and preclinical studies with partially purified material (3) appeared to support these early hopes. Recombinant TNF was selectively cytotoxic for some tumor cell lines (4) and caused necrosis of certain experimental syngeneic murine tumors (5) and human tumor xenografts (6) . However, in contrast to the antitumor action observed in these earlier studies, a number ofbiological activities were identified that could promote the growth and invasive capacity oftumors (7) . TNF may act directly as a growth factor for fibroblasts (8) and thus may contribute to the generation of tumor stroma (9) . TNF also has wide ranging effects on endothelial cells including promoting chemotaxis, the induction of proliferation, and stimulation of angiogenesis (10, 11) . TNF upregulates certain metalloproteinase genes ( 12, 13) that are associated with high invasive activity and metastatic potential ( 14) . Further actions include alterations in the expression of surface adhesion molecules ( 15, 16) increasing tumor cell binding to endothelium ( 17) . TNF also has potent effects on osteoclast activity, thereby stimulating bone resorption (18) . The role of TNF in cancer cachexia is still contentious, though experiments in rat models have provided some evidence that suggest a role in this complex wasting syndrome ( 19) .
We have previously demonstrated that TNF can promote tumor progression in vivo. In xenograft models, intraperitoneal injection of recombinant human TNF causes ascitic human ovarian cancer cells to clump and form multiple solid tumors on the peritoneal surface (20) . Moreover, cells transfected with TNF exhibited enhanced invasive capacity in nude mice, an effect that could be neutralized with antibodies to TNF (21 ) . Other groups have shown that certain human tumor cell lines express TNF in vitro and that prolonged exposure to TNF led to the development of resistance to the cytotoxic effects ofTNF and induced constitutive secretion ofTNF by these cells (22) .
We and others (23, 24) have demonstrated TNF expression in colorectal carcinoma in vivo by Northern analysis of extracted mRNA. In situ hybridization localized this expression to < 0.1% of infiltrating macrophages. No TNF gene expression was found in the neoplastic epithelial cells in these cancers. Similar results have been seen in studies on breast carcinomas (Miles, D., L. Happerfield, S. Naylor, L. Bobrow, and F. R. Balkwill, manuscript submitted for publication). In a preliminary study of 14 cases of human ovarian cancer (25) , we found a different pattern ofTNF gene expression, with localization to tumor epithelial areas. Of the common human cancers, ovarian carcinoma offers an insight into differing modes of progression; spreading by local expansion, direct invasion, transcoeloemic spread, and lymphatic or vascular invasion. The animal data and our initial findings indicate that human ovarian cancer offers a unique system for the analysis of TNF were either benign ovarian or nonovarian tumors (three thecoma, four mucinous cystadenomas, one squamous carcinoma ofcervix, one leiomyoma, one leiomyosarcoma, three metastatic colonic carcinoma, one granulosa cell tumor, one immature teratoma, one endometrioma, one malignant mixed mullerian tumor, and one appendiceal mucinous carcinoma). After identification of the 11 borderline tumors (carcinoma of low malignant potential), a scoring system was used to grade the frankly malignant ovarian carcinomas taking into account architectural and cytological features (27) . This grading was performed blind and independent of the assessments of immunostaining and in situ hybridization.
Tumor samples
Solid tumor specimens were snap frozen in liquid nitrogen immediately after removal from the patient. Normal ovarian tissue was also obtained from patients who had no evidence of ovarian neoplasia. For RNA isolation, solid tumor was cut into 1 0-Mm slices on an ultramicrotome and transferred into 5 M guanidinium thiocyanate lysis buffer. For in situ hybridization, 5-7-im sections were taken onto baked glass slides coated with triethoxysilylethanolamine (Sigma Immunochemicals, Poole Dorset, UK), air dried, fixed in freshly prepared 4% paraformaldehyde for 20 min, and stored dessicated at -70°C until required.
Cell lines
The HL60 human promyelocytic leukemic line was maintained in RPMI 1640 supplemented with 5% FCS. RNA was extracted for Northern analysis, and cytospins prepared for in situ hybridization after a 3-h incubation with 50 ng/ml PMA (Sigma Immunochemicals). This provided a source of TNF, IL-l a, and fi mRNA for use as a positive control in all RNA analyses (28) . Human foreskin fibroblasts were used as a source of IL-6 mRNA.
Probes IN SITU HYBRIDIZATION
TNF. An antisense TNF riboprobe was generated from the Apa 1-cleaved pGEM l-hTNF containing a 1-kb sequence of the TNF cDNA (obtained from Prof. W. Fiers, University of Ghent, Ghent, Belgium) using T7 RNA polymerase (Promega Biotech, Madison, WI). The negative control was sense TNF generated from Bam H 1 cleaved pGEM 1-hTNF using SP6 RNA polymerase (Promega Biotech).
IL-I a and fl. Antisense IL-I a and 3 probes were prepared from EcoRI cleaved pSPhIL-la and f plasmids, respectively (containing 400 bp Hind III/EcoR 1 fragment of the respective cDNAs, obtained from Dr. A. Shaw, Biogen, Geneva).
IL-6. The IL-6 probe was prepared from pGEM3 containing a 300-bp Taq l-Xba In situ hybridization
In situ hybridization was carried out on cryostat sections under ribonuclease limited conditions using 35S-labeled riboprobes as described previously (23) .
The sections were examined by direct illumination and dark field microscopy using a Leitz Diaplan microscope. Positive cells were identified by deposition of silver grains per cell in a concentration over the perinuclear cytoplasm that exceeded the "background" and levels on sections exposed to the "sense" probes by a factor of 2 10, and also reproduced a similar labeling density and pattern on duplicate sections. For relative abundance of labeled cells, an arbitrary scoring system of average labeling was used. Measurements were based on the mean number of labeled cells per high power field (hpf).' A minimum of 10 randomly selected hpfand up to 50 hpfwere counted using an eyepiece with a magnification of 10 and an objective lens with a magnification of 40 and field area = 3.2 mm2.
In Table I (21 ) .
TNF receptor. htr-9 (recognizes the p55 TNF receptor) and utr antibodies (recognizing the p75 TNF receptor) See reference 33.
Endogenous alkaline phosphatase activity was quenched with levamisole (31 ), endogenous peroxidase activity was blocked by preincubation with hydrogen peroxidase (30) .
Isolation ofDNA DNA was isolated according to standard procedures (34) .
Southern blot analysis an 0.7% agarose gel buffered at 40 V overnight. Ethidium bromide was added to the gel at 0.5 mg/ml. 5 ,ug of X DNA-Hind III OX -174 DNAHae III digest was run in one lane as size marker. After electrophoresis, the gel was depurinated in 0.25 M HCI for 15 min, neutralized in 0.4 M NaOH for 5 min, and then alkaline blotted (in 0.4M NaOH) onto genescreen. The membrane was rinsed in 2x SSC and left to air dry for 2 h. Blots were reprobed with a single copy probe to control for loading inaccuracies.
Isolation ofcellular RNA Total cellular RNA was isolated after centrifugation through cesium chloride followed by precipitation with 3 M sodium acetate and ethanol as described in (35) .
Northern blotting analysis 15-gg aliquots of total cellular RNA were electrophoresed through a (37) . Membranes were subsequently washed to high stringency and exposed to Kodak XAR5 film at -70°C with two intensifying screens (Dupont, Stevenage, Herts, UK).
Radiommunoassayfor TNF
The concentration of TNF was determined by radioimmunoassay using TNF-a IRMA kit (Medgenix, Medgenix Diagnostics, Fleurus, Belgium). The sensitivity of this assay is < 10 pg/ml.
Soluble TNF receptor assay
These were performed by Dr. Dan Aderka in the laboratory of Prof. David Wallach at the Weizmann Institute (Rehovot, Israel) (38) .
Results
Ovarian cancers TNF expression. TNF gene expression was found in 45 out of 63 cases ofovarian cancer and was localized to epithelial tumor areas. These data are summarized in Table I . The majority of serous carcinomas contained labeled cells (29 out of 40) in clusters of two to five cells within the epithelial compartment, and not within the intervening desmoplastic stroma (Fig. 1, a and b). Up to 65% of cells in a maximal hpf were found to express TNF (see Fig. 1 a) TNF receptor expression and immunolocalization. TNF p55 receptor expression was detected in all cases studied (n = 12). Of these cases, five were serous tumors, three were endometrioid, two were mucinousand, and two were undifferentiated. All but one of these had detectable TNF mRNA in the epithelial compartment. The p55 receptor expression was confined to the epithelial tumor cells yet in a more homogeneous distribution than that ofTNF mRNA expression (see Fig. 4 , B and F). The distribution and extent oflabeling was more easily appreciated by dark field microscopy (see Fig. 4 , a, c, and e). The macrophages within the glandular lumina did not appear to express the p55 receptor. In contrast, p75 TNF receptor expression was not seen in the malignant glandular epithelium, but was found at the tumor-stromal interface and over cells in the malignant gland lumina (Fig. 4 d) . This related to the macrophage distribution on adjacent sections (not shown).
Immunohistochemistry with the htr antibody (recognizing the p55 receptor) showed a weak to moderate localization that was present in the majority of epithelial cells and appeared to reflect the in situ hybridization results. The utr antibody (recognizing the p75 receptor) localized to some cells in the stroma and within malignant glandular spaces corresponding to the p75 mRNA distribution and the distribution of macrophages. p75 immunostaining was not observed on epithelial cells.
Expression of TNF-related cytokines. Expression of other cytokines was investigated in relation to TNF expression. IL-1,B expression was found in 23 out of 68 cases assessed. In 20 of these cases expressing IL-1B, TNF was also expressed. The distribution and extent of IL-13 mRNA was unlike that of TNF. IL-13 gene expression was scattered, found at lower levels (generally < 0.1% of the population, though in one case < 23% of cells in the highest expressing area) and localized to the boundaries of stroma and epithelium. In many cases, IL-1 # expression showed a similar distribution to that of the macrophage population. IL-la mRNA was not detected in any ofthe cases, though it could be detected in the HL60 control. IL-6 expression was found in 2 out of 12 cases (both of which were TNF and IL-1# negative), and localized to stromal areas in clusters again usually in a single high power field consisting of 7 and 8% of the field.
Ovarian cancer ascites Cytospin preparations from the ascitic fluids of nine patients were examined. Seven of the nine samples contained malignant cells. In the other two cases, one had inflammatory and mesothelial cells only, and the other showed marked degenerative changes with no recognizable malignant cells. In situ analysis for TNF mRNA showed clear labeling (relative to sense probed controls) in three of the seven cases containing malignant cells. One case showed light labeling on 45% ofmalignant cell clusters, another showed labeling on malignant cells and 1-2% of inflammatory cells (see Fig. 5 ), and the remaining case showed occasional labeling of mononuclear cells (< 1% total cell population) and no localization to the malignant cell population. Mesothelial cells did not show labeling in any of the cases studied.
Normal ovary
In 2 out of 12 biopsies of nonneoplastic ovary, a small proportion of cells expressed TNF mRNA. In both cases, these cells localized to focal areas of the externa theca of the corpus luteum (Fig. 6) . Normal ovarian mesothelium, stroma, and follicles did not contain TNF mRNA as assessed by this methodology.
DNA and RNA analysis
To investigate gross genetic changes at the TNF locus, Southern blots were run on DNA extracted from 40 matched tumor and normal tissue samples in parallel with single copy controls. There appeared to be no significant amplification of the TNF gene in tumor relative to matched normal tissue and band shifts were not detected at this level ofanalysis, suggesting there are no gross abnormalities at the TNF locus in these tumors relative to the normal tissue controls. (Data not shown.)
Northern analysis was performed on five of the most positive cases to determine any aberrances in transcript size. No significant changes in the size ofthe TNF transcript were determined as assessed by electrophoretic mobility relative to an HL60 control RNA sample. (Data not shown.) Serum and ascites assays for TNF and TNF receptor proteins Levels of soluble TNF receptor and TNF protein in serum and ascites of ovarian cancer patients were also investigated (see Fig. 7) .
In cases where matched material (n = 42) was available, there appeared to be no significant correlation with expression in the tumor and levels of TNF protein and receptors in the serum, although the two cases where the highest levels of TNF protein were detected also showed high levels of TNF expression within the tumor. Samples of matched serum and ascitic fluid were obtained from three patients. In these cases, levels of TNF protein were significantly higher in ascites than in the matched serum; i.e., in one case, levels ofTNF were undetected in the serum, whereas in the ascites, levels of 206 pg/ml were recorded. Levels of soluble TNF receptor in the serum ofthese patients were not significantly higher than . , S -. ; 4 S . < d | ' ' S s ' : : . .
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Discussion
In this study, we have demonstrated dysregulated expression and production of TNF and its receptors to an extent and dis- . There appears to be no signifi- 20 cant correlation with expression in the tumor and levels of TNF protein and receptor in the serum,°t hough the two cases where the highest levels of TNF protein were detected also showed higher levels of TNF expression within the tumor. TNF produced in ovarian cancers may be able to promote tumorigenesis by increasing local vasculature ( 11), and by inducing tissue remodeling ( 18) . Our in situ hybridization studies indicate that TNF appears to be expressed by ascitic cells and high levels of TNF protein are found in these ascitic fluids. TNF may alter adhesion events in the ascitic stage of the disease that contribute to implantation as demonstrated in previous studies on our ovarian cancer xenografts (20, 21 ) . Recombinant TNF has been used successfully in the resolution of cancer ascites (46), although there is no evidence that this treatment extends patient survival. Our previous studies (20, 21 ) indicate that the ascitic cells may not be eradicated but that the TNF causes a change in the biology ofthe tumor that leads to tumor implantation in these cases.
Soluble TNF receptors have been found at high levels in a number of disease states including ovarian cancer (38) . While the cellular source of these TNF binding proteins has not been determined, our in situ results may provide the answer. In this study, the data does not show any significant increase in TNF receptor levels relative to normal samples, although there is clearly a need to look at ascites samples that would be a better indicator of local receptor shedding. The importance of looking in the ascitic fluid is underlined by our detection of high Analysis of normal ovarian tissue indicated that TNF is not usually produced by nonneoplastic ovarian cells or stroma. It is interesting that a minority of cells in the thecal layer of the corpus luteum expressed TNF mRNA in 2 of 12 normal samples. The reason for TNF expression in normal ovary has yet to be determined, but it may reflect the role TNF has in the general wound healing response (9) .
Production of TNF by ovarian cancer cells could result in resistance to the cytotoxic action of host derived TNF (22) or exogenous rhuTNF administered in a therapeutic setting. TNF has been used in several clinical trials in cancer patients and has resulted in no significant improvements in survival. Local production by tumor cells and their consequent resistance may in part explain these disappointing results.
Our study has demonstrated a high degree of expression and production of TNF and its receptors in ovarian cancer. This phenomenon appears to be peculiar to this cancer type in that the majority ofexpression is confined to the epithelial cells that do not normally express this cytokine in vivo. We have also observed a relationship with tumor grade and TNF expression in serous ovarian cancer. The higher incidence of TNF expression may be caused by the increased cell density in high grade tumors and the relative increase in infiltrating cells found in these cases. Increases in the proportion ofmacrophages may result in more TNF secreted into the tumor microenvironment with increased ability to induce TNF expression in the tumor epithelial cells. The relative distribution of macrophages suggests a role for these cells in the induction of TNF expression. The aberrant expression of this potent cytokine and its actions in promoting tumor spread may indicate that TNF therapy would be inappropriate for some ovarian cancers and that TNF antagonists would be more effective.
